Open Clinical Trials - Ironwood Cancer & Research Centers

Ironwood Cancer & Research Centers are committed to the advancement of medical knowledge and patient care. Medical research has and continues to transform the practice of medicine resulting in a high quality of care we enjoy today. We believe that by supporting clinical research today, we are helping build the future of medicine and the profound developments that are sure to come. We have an active and expanding clinical research program.

We have a comprehensive team of physician investigators, research nurses, clinical research coordinators, research assistants and regulatory specialist serving all our offices. This allows us to provide the option for our eligible patients to the latest therapies and treatments. If you are interested in participating in a clinical trial, please talk to your physician or call our research department at 480-398-7671. Learn more about participating in a clinical trial here.

Current Studies at Ironwood Cancer & Research Centers

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov ID NCT07005102

Protocol number M25-287

Sponsor AbbVie

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-5)

ClinicalTrials.gov ID NCT07276399

Protocol number 61186372HNC3001

Sponsor Janssen Research & Development, LLC

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

ClinicalTrials.gov ID NCT06129864

Protocol number

Sponsor AstraZeneca

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (KANDELA-302)

ClinicalTrials.gov ID NCT07492641

Protocol number BGB-43395-302

Sponsor BeOne Medicines

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov ID NCT07043400

Protocol number BGB-A317-316

Sponsor BeOne Medicines

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov ID NCT07222566

Protocol number C6461001

Sponsor Pfizer

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung17)

ClinicalTrials.gov ID NCT05215340

Protocol number D763QC00001

Sponsor Astra Zeneca

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

ClinicalTrials.gov ID NCT05215340

Protocol number DS1062- A- U304

Sponsor Daiichi Sankyo

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID NCT06568939

Protocol number M25-274

Sponsor AbbVie

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

ClinicalTrials.gov ID NCT07028853

Protocol number C2321008

Sponsor Pfizer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

ClinicalTrials.gov ID NCT07062965

Protocol number C4551002

Sponsor Pfizer

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

ClinicalTrials.gov ID NCT06129864

Protocol number D798EC00001

Sponsor Astra Zeneca

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7)

ClinicalTrials.gov IDNCT06767514

Protocol number SMT112-3007

Sponsor Summit

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

ClinicalTrials.gov ID NCT06445062

Protocol number RMC-GI-102

Sponsor Revolution Medicines, Inc.

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)

ClinicalTrials.gov ID NCT06492616

Protocol number STML-ELA-0422

Sponsor Stemline Therapeutics, Inc.

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov ID NCT06629779

Protocol number PF-06821497

Sponsor Pfizer

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

ClinicalTrials.gov ID NCT06841354

Protocol number MK-2870-011

Sponsor Merck Sharp & Dohme LLC

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

ClinicalTrials.gov ID NCT06629779

Protocol number PF 06821497

Sponsor Pfizer

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

ClinicalTrials.gov ID NCT06562543

Protocol number TAK-113-4002

Sponsor Takeda

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ClinicalTrials.gov ID NCT06588478

Protocol number J2N-MC-JZNX

Sponsor Loxo Oncology, Inc.

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

ClinicalTrials.gov ID NCT06246916

Protocol number R3767-ONC-22122

Sponsor Regeneron Pharmaceuticals, Inc.

Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

ClinicalTrials.gov ID NCT06697301

Protocol number EIK1001-006

Sponsor Eikon Therapeutics

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

ClinicalTrials.gov ID NCT06312176

Protocol number MK2870-010

Sponsor Merck Sharp & Dohme LLC

Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

ClinicalTrials.gov ID NCT06377852

Protocol number 00075309

Sponsor American Society of Clinical Oncology

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

ClinicalTrials.gov ID NCT06252649

Protocol number AMG 20210081

Sponsor Amgen

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

ClinicalTrials.gov ID NCT06393374

Protocol number MK-2870-012

Sponsor Merck Sharp & Dohme LLC

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)

ClinicalTrials.gov ID NCT05059444

Protocol number 02-MX-003

Sponsor Guardant Health, Inc.

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

ClinicalTrials.gov ID NCT05211895

Protocol number PACIFIC-8 D9075C00001

Sponsor Astra Zeneca

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

ClinicalTrials.gov ID NCT06003231

Protocol number SGNDV-005

Sponsor Seagen Inc.

*Cohort Closed at this time*

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

ClinicalTrials.gov ID NCT05199818

Protocol number LP-CT-PALO-202101

Sponsor Xiamen LP Pharmaceutical Co., Ltd

Resources

Academic Cancer Care

Current Studies at Ironwood Cancer & Research Centers

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov ID NCT07005102

Protocol number M25-287

Sponsor AbbVie

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/​Metastatic Head and Neck Cancer (OrigAMI-5)

ClinicalTrials.gov ID NCT07276399

Protocol number 61186372HNC3001

Sponsor Janssen Research & Development, LLC

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

ClinicalTrials.gov ID NCT06129864

Protocol number

Sponsor AstraZeneca

BGB-43395 Plus Letrozole Versus CDK4/​6i Plus Letrozole for Patients With Advanced or Metastatic HR+/​HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (KANDELA-302)

ClinicalTrials.gov ID NCT07492641

Protocol number BGB-43395-302

Sponsor BeOne Medicines

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov ID NCT07043400

Protocol number BGB-A317-316

Sponsor BeOne Medicines

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov ID NCT07222566

Protocol number C6461001

Sponsor Pfizer

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung17)

ClinicalTrials.gov ID NCT05215340

Protocol number D763QC00001

Sponsor Astra Zeneca

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

ClinicalTrials.gov ID NCT05215340

Protocol number DS1062- A- U304

Sponsor Daiichi Sankyo

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID NCT06568939

Protocol number M25-274

Sponsor AbbVie

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

ClinicalTrials.gov ID NCT07028853

Protocol number C2321008

Sponsor Pfizer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

ClinicalTrials.gov ID NCT07062965

Protocol number C4551002

Sponsor Pfizer

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

ClinicalTrials.gov ID NCT06129864

Protocol number D798EC00001

Sponsor Astra Zeneca

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7)

ClinicalTrials.gov IDNCT06767514

Protocol number SMT112-3007

Sponsor Summit

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

ClinicalTrials.gov ID NCT06445062

Protocol number RMC-GI-102

Sponsor Revolution Medicines, Inc.

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)

ClinicalTrials.gov ID NCT06492616

Protocol number STML-ELA-0422

Sponsor Stemline Therapeutics, Inc.

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov ID NCT06629779

Protocol number PF-06821497

Sponsor Pfizer

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/​TroFuse-011)

ClinicalTrials.gov ID NCT06841354

Protocol number MK-2870-011

Sponsor Merck Sharp & Dohme LLC

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

ClinicalTrials.gov ID NCT06629779

Protocol number PF 06821497

Sponsor Pfizer

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

ClinicalTrials.gov ID NCT06562543

Protocol number TAK-113-4002

Sponsor Takeda

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-5)

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (KANDELA-302)

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)